MedTrace Logo

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

NCT05656794 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-23

No results posted yet for this study

Summary

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Conditions

  • Prostate Metastases

Interventions

RADIATION

Radiotherapy

Standard of care radiotherapy administered as per institutional guidelines.

Sponsors & Collaborators

  • TerSera Therapeutics LLC

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-09
Primary Completion
2031-08-31
Completion
2031-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656794 on ClinicalTrials.gov